Earnings Releases·Nov 5, 2026, 4:36 PM ET

Nkarta — Third Quarter 2026 Earnings Summary

Reported a net loss of $33.3 million ($0.45 per share) for Q3 2026, widening from $21.7 million ($0.29 per share) in the prior year period, driven by a 46% increase in R&D expenses to $29.5 million.
Cash, cash equivalents, restricted cash, and investments declined to $216.0 million as of September 30, 2026, from $295.1 million at year-end 2025, though management expects current liquidity to fund operations through 2029.
Clinical progress includes ongoing enrollment in the Ntrust program with outpatient dosing at 12 billion cells total per patient, with initial data for myositis and systemic sclerosis scheduled for presentation at ACR Convergence 2026.
The company remains a clinical-stage entity with no approved products, facing risks related to limited operating history, manufacturing complexity, and the potential for preliminary clinical data to change as follow-up increases.